South by Southwest interactive (SXSWi) had a lot more mobile health content than usual, a sign that it’s hit the mainstream. The issues tackled were:
- Retention is the hard part: getting uptake on a mobile health initiative may be difficult but it pales in comparison with keeping people there.
- FDA approval rules: the market is somewhat shaped by what needs approval and what does not. Stories from Azumio’s Jennifer Genz about patients using the data from the tool to self-diagnose a heart attack before it happened are great, but may make the FDA tighten rules about what needs 510(k) certification, even if Azumio doggedly claims that it does not provide “diagnostic” advice. Meanwhile, the cautionary tale of 23andMe continues with the company admitting that the FDA’s injunction “significantly slowed up” new customer flow.
23andMe co-founder Anne Wojciki said about the FDA injunction:
“But we have 650,000 people in our database and are being inundated with requests from academics and foreign partners. We have more of this data than anyone else in the world… We are pioneers. We’ve had a lot of ups and downs but we have lots of tenacity to push on through. It will take time money and effort to figure out the path forward.”
Other stories from MobiHealthNews:
- Health researchers see unique opportunity in self-tracker data
- 15 health and fitness apps Apple calls “essential”
- UC Davis taps Ginger.io for psychotic illness study